{"title":"Panitumumab (Vectibix): serious hypersensitivity reactions","public_updated_at":"2014-12-11T14:29:06Z","details":{"metadata":{"therapeutic_area":["cancer"],"first_published_at":"2010-05-01T00:00:00Z","bulk_published":true,"document_type":"drug_safety_update"},"change_history":[{"note":"First published.","public_timestamp":"2014-12-11T14:29:06.000Z"},{"note":"First published.","public_timestamp":"2014-12-11T14:29:06.000Z"}],"body":[{"content_type":"text/html","content":"<p>Article date: May 2010</p>\n\n<p>Panitumumab (Vectibix) is indicated as monotherapy for the treatment of patients with EGFR (epidermal growth factor receptor)-expressing metastatic colorectal carcinoma with non-mutated (wild type) KRAS after failure of chemotherapy regimens.</p>\n\n<p>There have been new reports of serious hypersensitivity reactions (including anaphylaxis) in patients receiving panitumumab, some of which were fatal.</p>\n\n<p>A clinical trial report has been received of a fatal case of angioedema occurring 2 days after exposure following a prior episode of angioedema which occurred 6 days after exposure. Recently, two case reports of fatal hypersensitivity reactions during and immediately following panitumumab infusion have been received; these patients had previously experienced hypersensitivity reactions to cetuximab and oxaliplatin, respectively.</p>\n\n<div class=\"call-to-action\">\n<h3 id=\"advice-for-healthcare-professionals\">Advice for healthcare professionals</h3>\n\n<p>Panitumumab is contraindicated in patients with a history of severe or life-threatening hypersensitivity reactions to this medicine.<br />\nSerious infusion-related reactions are unpredictable and can occur suddenly. Panitumumab should be permanently discontinued if a severe or life-threatening reaction occurs.<br />\n In patients with a mild or moderate infusion-related reaction, the infusion rate should be reduced for the duration of the infusion; it is recommended to maintain this lower infusion rate in all subsequent infusions.<br />\nHypersensitivity reactions occurring more than 24 hours after infusion have also been reported. Patients should be warned of a possible late-onset reaction and instructed to contact their physician if symptoms of hypersensitivity occur.</p>\n</div>\n\n<p><a rel=\"external\" href=\"http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/ssLINK/CON081746\">A letter has been sent to relevant healthcare professionals to inform of these risks</a>.</p>\n\n<p>Article citation: Drug Safety Update May 2010, vol 3 issue 10: 8.</p>\n"},{"content_type":"text/govspeak","content":"Article date: May 2010\r\n\r\nPanitumumab (Vectibix) is indicated as monotherapy for the treatment of patients with EGFR (epidermal growth factor receptor)-expressing metastatic colorectal carcinoma with non-mutated (wild type) KRAS after failure of chemotherapy regimens.\r\n\r\nThere have been new reports of serious hypersensitivity reactions (including anaphylaxis) in patients receiving panitumumab, some of which were fatal.\r\n\r\nA clinical trial report has been received of a fatal case of angioedema occurring 2 days after exposure following a prior episode of angioedema which occurred 6 days after exposure. Recently, two case reports of fatal hypersensitivity reactions during and immediately following panitumumab infusion have been received; these patients had previously experienced hypersensitivity reactions to cetuximab and oxaliplatin, respectively.\r\n\r\n$CTA\r\n\r\n###Advice for healthcare professionals\r\n  \r\nPanitumumab is contraindicated in patients with a history of severe or life-threatening hypersensitivity reactions to this medicine.  \r\nSerious infusion-related reactions are unpredictable and can occur suddenly. Panitumumab should be permanently discontinued if a severe or life-threatening reaction occurs.  \r\n In patients with a mild or moderate infusion-related reaction, the infusion rate should be reduced for the duration of the infusion; it is recommended to maintain this lower infusion rate in all subsequent infusions.  \r\nHypersensitivity reactions occurring more than 24 hours after infusion have also been reported. Patients should be warned of a possible late-onset reaction and instructed to contact their physician if symptoms of hypersensitivity occur.  \r\n$CTA\r\n  \r\n[A letter has been sent to relevant healthcare professionals to inform of these risks](http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/ssLINK/CON081746).\r\n\r\nArticle citation: Drug Safety Update May 2010, vol 3 issue 10: 8.\r\n"}],"max_cache_time":10,"temporary_update_type":false},"routes":[{"path":"/drug-safety-update/panitumumab-vectibix-serious-hypersensitivity-reactions","type":"exact"}],"redirects":[],"publishing_app":"specialist-publisher","rendering_app":"government-frontend","need_ids":[],"phase":"live","analytics_identifier":null,"document_type":"drug_safety_update","schema_name":"specialist_document","first_published_at":"2016-02-29T09:24:10Z","base_path":"/drug-safety-update/panitumumab-vectibix-serious-hypersensitivity-reactions","description":"New reports of serious hypersensitivity reactions (including anaphylaxis) in patients receiving panitumumab, some of which were fatal.","content_id":"43cb773c-c5ad-4b3c-af53-ba9889ae32ec","locale":"en","expanded_links":{"organisations":[{"analytics_identifier":"EA63","api_path":"/api/content/government/organisations/medicines-and-healthcare-products-regulatory-agency","base_path":"/government/organisations/medicines-and-healthcare-products-regulatory-agency","content_id":"240f72bd-9a4d-4f39-94d9-77235cadde8e","description":null,"document_type":"organisation","locale":"en","public_updated_at":"2015-06-29T14:33:29Z","schema_name":"placeholder","title":"Medicines and Healthcare products Regulatory Agency","withdrawn":false,"details":{"brand":"department-of-health","logo":{"formatted_title":"Medicines &amp; Healthcare products<br/>Regulatory Agency","crest":"single-identity"}},"links":{}}],"finder":[{"analytics_identifier":null,"api_path":"/api/content/drug-safety-update","base_path":"/drug-safety-update","content_id":"602be505-4cf4-4f8c-8bfc-7bc4b63a7f47","description":"Find drug safety updates issued by MHRA","document_type":"finder","locale":"en","public_updated_at":"2017-03-30T10:34:00Z","schema_name":"finder","title":"Drug Safety Update","withdrawn":false,"details":{"document_noun":"update","filter":{"document_type":"drug_safety_update"},"format_name":"Drug Safety Update","show_summaries":true,"facets":[{"key":"therapeutic_area","name":"Therapeutic area","type":"text","preposition":"about","display_as_result_metadata":true,"filterable":true,"allowed_values":[{"label":"Anaesthesia and intensive care","value":"anaesthesia-intensive-care"},{"label":"Cancer","value":"cancer"},{"label":"Cardiovascular disease and lipidology","value":"cardiovascular-disease-lipidology"},{"label":"Dentistry","value":"dentistry"},{"label":"Dermatology","value":"dermatology"},{"label":"Ear, nose and throat","value":"ear-nose-throat"},{"label":"Endocrinology, diabetology and metabolism","value":"endocrinology-diabetology-metabolism"},{"label":"GI, hepatology and pancreatic disorders","value":"gi-hepatology-pancreatic-disorders"},{"label":"Haematology","value":"haematology"},{"label":"Immunology and vaccination","value":"immunology-vaccination"},{"label":"Immunosuppression and transplantation","value":"immunosuppression-transplantation"},{"label":"Infectious disease","value":"infectious-disease"},{"label":"Neurology","value":"neurology"},{"label":"Nutrition and dietetics","value":"nutrition-dietetics"},{"label":"Obstetrics, gynaecology and fertility","value":"obstetrics-gynaecology-fertility"},{"label":"Ophthalmology","value":"ophthalmology"},{"label":"Paediatrics and neonatology","value":"paediatrics-neonatology"},{"label":"Pain management and palliation","value":"pain-management-palliation"},{"label":"Psychiatry","value":"psychiatry"},{"label":"Radiology and imaging","value":"radiology-imaging"},{"label":"Respiratory disease and allergy","value":"respiratory-disease-allergy"},{"label":"Rheumatology","value":"rheumatology"},{"label":"Urology and nephrology","value":"urology-nephrology"}]},{"key":"first_published_at","name":"Published","short_name":"Published","type":"date","preposition":"published","display_as_result_metadata":true,"filterable":true}],"default_documents_per_page":50},"links":{}}],"available_translations":[{"title":"Panitumumab (Vectibix): serious hypersensitivity reactions","public_updated_at":"2014-12-11T14:29:06Z","analytics_identifier":null,"document_type":"drug_safety_update","schema_name":"specialist_document","base_path":"/drug-safety-update/panitumumab-vectibix-serious-hypersensitivity-reactions","description":"New reports of serious hypersensitivity reactions (including anaphylaxis) in patients receiving panitumumab, some of which were fatal.","api_path":"/api/content/drug-safety-update/panitumumab-vectibix-serious-hypersensitivity-reactions","withdrawn":false,"content_id":"43cb773c-c5ad-4b3c-af53-ba9889ae32ec","locale":"en"}]},"format":"specialist_document","navigation_document_supertype":"other","user_journey_document_supertype":"thing","email_document_supertype":"other","government_document_supertype":"other","payload_version":0}